Polymorphisms of GSTP1, ERCC2 and TS-3′UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients

Oncology Letters

Volumn 6, Issue 3, 2013, Pages 648-654

  Kumamoto, Kensuke ^a   Ishibashi, Keiichiro ^a   Okada, Norimichi ^a   Tajima, Yusuke ^a   Kuwabara, Kouki ^a   Kumagai, Yoichi ^a   Baba, Hiroyuki ^a   Haga, Norihiro ^a   Ishida, Hideyuki ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; FOLFOX; Polymorphism

Indexed keywords

5, 10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BEVACIZUMAB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; IRINOTECAN; OXALIPLATIN; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; DNA POLYMORPHISM; DRUG DOSE REDUCTION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT RESPONSE;

EID: 84880419972     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1467     Document Type: Article

References (31)

1. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
2. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004.
3. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004.
4. Reddy GK, Gibson AD and Price N: Evolution of FOLFOX regimens in the treatment of advanced colorectal cancer. Clin Colorectal Cancer 4: 296-299, 2005.
5. Shimizu T, Satoh T, Tamura K, et al: Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience. Int J Clin Oncol 2: 218-223, 2007.
6. Leichman CG, Lenz HJ, Leichman L, et al: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229, 1997.
7. Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327, 2000.
8. Shirota Y, Stoehlmacher J, Brabender J, et al: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19: 4298-4304, 2001.
9. Kim SH, Kwon HC, Oh SY, et al: Prognostic value of ERCC1, thymidylate synthase and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol 32: 38-43, 2009.
10. Kumamoto K, Kuwabara K, Tajima Y, et al: Thymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis. Oncol Lett 3: 983-989, 2012.
11. Stoehlmacher J, Park DJ, Zhang W, et al: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91: 344-354, 2004.
12. Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, et al: Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol 69: 58-66, 2010.
13. Ruzzo A, Graziano F, Loupakis F, et al: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25: 1247-1254, 2007.
14. Boige V, Mendiboure J, Pignon JP, et al: Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX and FOLFIRI: FFCD 2000-05. J Clin Oncol 28: 2556-2564, 2010.
15. Ma J, Stampfer MJ, Giovannucci E, et al: Methylenetetrahydrofolate reductase polymorphism, dietary interactions and risk of colorectal cancer. Cancer Res 57: 1098-1102, 1997.
16. van der Put NM, Gabreëls F, Stevens EM, et al: A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 62: 1044-1051, 1998.
17. Park DJ, Stoehlmacher J, Zhang W, et al: ERCC1 gene polymorphism is associated with differential ERCC1 gene expression. Proc AACR 93: 1591, 2002.
18. Park DJ, Zhang W, Stoehlmacher J, et al: ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 1: 162-166, 2003.
19. Chang PM, Tzeng CH, Chen PM, et al: ERCC1 codon 118 C>T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci 100: 278-283, 2009.
20. Park DJ, Stoehlmacher J, Zhang W, et al: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61: 8654-8658, 2001.
21. Stoehlmacher J, Park DJ, Zhang W, et al: Association between glutathione S-transferase P1, T1 and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94: 936-942, 2002.
22. Chen YC, Tzeng CH, Chen PM, et al: Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 101: 530-535, 2010.
23. Zarate R, Rodríguez J, Bandres E, et al: Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br J Cancer 102: 987-994, 2010.
24. Watson MA, Stewart RK, Smith GB, et al: Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19: 275-280, 1998.
25. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
26. Moscow JA, Fairchild CR, Madden MJ, et al: Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 49: 1422-1428, 1989.
27. Ban N, Takahashi Y, Takayama T, et al: Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan and etoposide. Cancer Res 56: 3577-3582, 1996.
28. Popat S, Matakidou A and Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22: 529-536, 2004.
29. Stoehlmacher J, Goekkurt E, Mogck U, et al: Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation. Cancer Lett 272: 221-225, 2008.
30. Dotor E, Cuatrecases M, Martínez-Iniesta M, et al: Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 24: 1603-1611, 2006.
31. Keam B, Im SA, Han SW, et al: Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer 8: 148, 2008.